Paper Details

  1. Home
  2. Paper Details

TRK inhibitors in TRK fusion-positive cancers.

Author: DrilonA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

TRK inhibitors, such as larotrectinib and entrectinib, are effective in treating various cancers with TRK fusions, including those with brain metastases. While resistance can occur, next-generation inhibitors like selitrectinib and repotrectinib are being developed to overcome this. Although TRK inhibitors have a good safety profile, some on-target side effects like weight gain and dizziness can occur.
Paper Details　
Original Abstract of the Article :
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively. Brisk and durable responses ar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859818/

データ提供：米国国立医学図書館（NLM）

TRK Inhibitors: A Promising New Frontier in Cancer Treatment

TRK fusions, genetic alterations that drive the growth of certain cancers, have become a hot topic in oncology. This study delves into the exciting world of TRK inhibitors, a class of drugs specifically designed to target these oncogenic drivers. The researchers discuss the recent approval of first-generation TRK inhibitors, larotrectinib and entrectinib, for the treatment of TRK fusion-positive cancers, regardless of the tumor's location. They also highlight the development of next-generation TRK inhibitors, such as selitrectinib and repotrectinib, which aim to overcome resistance to the first-generation drugs.

TRK Inhibitors: A New Era of Targeted Therapy

The approval of TRK inhibitors marks a significant advancement in cancer treatment. These targeted therapies offer the potential for effective and durable responses in patients with TRK fusion-positive cancers. The development of next-generation inhibitors further expands the therapeutic options for these patients, providing hope for better outcomes.

A Journey Through the Desert of Cancer

Imagine a desert landscape with hidden oases, each one representing a potential treatment option. TRK inhibitors are like newly discovered oases, offering a refreshing escape from the harsh realities of cancer. These targeted therapies represent a beacon of hope, offering a chance to fight this challenging disease with greater precision and effectiveness.

Dr.Camel's Conclusion

TRK inhibitors represent a significant step forward in our fight against cancer. These targeted therapies offer a glimmer of hope for patients with TRK fusion-positive cancers, and the development of next-generation inhibitors provides further optimism. This journey through the desert of cancer is ongoing, but with continued research and innovation, we are steadily finding new ways to combat this formidable adversary.

Date :
  1. Date Completed 2020-07-08
  2. Date Revised 2023-10-19
Further Info :

Pubmed ID

31738426

DOI: Digital Object Identifier

PMC6859818

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.